Literature DB >> 2173884

Secondary T-cell lymphoproliferation after marrow transplantation.

M M Zutter1, D M Durnam, R C Hackman, T P Loughran, P G Kidd, R L Ashley, E W Petersdorf, P J Martin, E D Thomas.   

Abstract

Secondary lymphoproliferative syndromes in immunosuppressed patients have been characterized as polyclonal or monoclonal B-lineage disorders nearly always associated with Epstein-Barr virus (EBV) infection. The authors now report three patients with a distinctly different lymphoproliferative syndrome. Two patients with common acute lymphoblastic leukemia antigen (CALLA) (CD10)-positive acute lymphoblastic leukemia and one patient with acute myelogenous leukemia, respectively, received high-dose chemoradiotherapy followed by marrow transplantation from either an HLA-identical sibling or HLA-mismatched parent. All three patients developed severe graft-versus-host disease (GVHD), requiring immunosuppressive treatment with corticosteroids. A secondary malignant T-cell lymphoproliferation occurred 2, 21, and 43 months, respectively, after marrow transplantation. In all three cases the lymphoid cells expressed T-cell surface antigens and were morphologically and immunophenotypically distinct from the malignant cells present before transplantation. One tumor was of host cell origin, one was probably of donor origin, and the tumor origin in the third case could not be determined. The authors were unable to find any evidence for EBV, human T-cell lymphotropic virus type I or II, human immunodeficiency virus, or human herpesvirus 6.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173884     DOI: 10.1093/ajcp/94.6.714

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

Review 1.  Primary cardiac post-transplantation lymphoproliferative disorder--T cell type: a case report and review of the literature.

Authors:  V Mahesha; K Joshi; V Jha; R Nada
Journal:  J Clin Pathol       Date:  2007-04       Impact factor: 3.411

Review 2.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

3.  On the crossroad between tolerance and posttransplant lymphoma.

Authors:  Michael A Nalesnik; Thomas E Starzl
Journal:  Curr Opin Organ Transplant       Date:  1997-10-01       Impact factor: 2.640

Review 4.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

5.  Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.

Authors:  Sun Hee Park; Su Mi Choi; Dong Gun Lee; Jung Hyun Choi; Jin Hong Yoo; Hee Je Kim; Dong Wook Kim; Jong Wook Lee; Woo Sung Min; Wan Shik Shin; Chun Choo Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 6.  Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy.

Authors:  Richard F Ambinder
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.